Published in Antimicrob Agents Chemother on May 18, 2015
Improved Protection in a Rabbit Model of Community-Associated Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia upon Neutralization of Leukocidins in Addition to Alpha-Hemolysin. Antimicrob Agents Chemother (2016) 0.83
Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections. Clin Infect Dis (2016) 0.80
Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893. Antimicrob Agents Chemother (2016) 0.80
How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem? MBio (2016) 0.80
Prevention and treatment of Staphylococcus aureus biofilms. Expert Rev Anti Infect Ther (2015) 0.79
Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs (2015) 0.79
Targeting Alpha Toxin to Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia. Antimicrob Agents Chemother (2017) 0.75
Phenol-Soluble Modulins Contribute to Early Sepsis Dissemination Not Late Local USA300-Osteomyelitis Severity in Rabbits. PLoS One (2016) 0.75
Pediatric Multiple Organ Dysfunction Syndrome: Promising Therapies. Pediatr Crit Care Med (2017) 0.75
NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol (2008) 13.49
Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med (2007) 5.95
Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest (2005) 5.91
ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A (2005) 3.57
A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med (2011) 3.17
Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One (2009) 2.60
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest (1998) 2.15
Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun (2009) 2.11
Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol (2011) 2.04
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) (2013) 1.99
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med (2014) 1.76
ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin. J Infect Dis (2012) 1.56
Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol (2012) 1.41
Staphylococcus aureus α-hemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 inflammasome. J Infect Dis (2012) 1.37
Staphylococcus aureus leukotoxin GH promotes inflammation. J Infect Dis (2012) 1.30
Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother (2013) 1.27
Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother (2013) 1.25
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother (2013) 1.24
Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus α-hemolysin. J Mol Biol (2013) 1.17
Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio. Antimicrob Agents Chemother (2013) 1.14
Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). J Antimicrob Chemother (2014) 1.06
Mechanisms of linezolid resistance among coagulase-negative staphylococci determined by whole-genome sequencing. MBio (2014) 0.98
Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem (2014) 0.98
Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob Agents Chemother (2014) 0.97
Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy (2006) 0.95
Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Rev Respir Med (2012) 0.90
A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis (2013) 0.89
PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis (2011) 0.87
Methicillin-resistant Staphylococcus aureus pneumonia in adults. Expert Rev Respir Med (2014) 0.84
Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol (2012) 1.33
Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother (2013) 1.25